First Wave Biopharma Reaches Enrollment Target for Phase II Span Adrulipase Clinical Trial in Cystic Fibrosis

First Wave BioPharma, Inc. announced that it has achieved the enrollment target in its ongoing Phase II SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.